1 Institute of Neurorestoratology, General Hospital of Armed Police Forces, Beijing, People's Republic of China.
2 W. M. Keck Center for Collaborative Neuroscience, Rutgers, State University of New Jersey, Piscataway, NJ, USA.
Cell Transplant. 2018 Feb;27(2):310-324. doi: 10.1177/0963689717746999.
Cell therapy has been shown to be a key clinical therapeutic option for central nervous system diseases or damage. Standardization of clinical cell therapy procedures is an important task for professional associations devoted to cell therapy. The Chinese Branch of the International Association of Neurorestoratology (IANR) completed the first set of guidelines governing the clinical application of neurorestoration in 2011. The IANR and the Chinese Association of Neurorestoratology (CANR) collaborated to propose the current version "Clinical Cell Therapy Guidelines for Neurorestoration (IANR/CANR 2017)". The IANR council board members and CANR committee members approved this proposal on September 1, 2016, and recommend it to clinical practitioners of cellular therapy. These guidelines include items of cell type nomenclature, cell quality control, minimal suggested cell doses, patient-informed consent, indications for undergoing cell therapy, contraindications for undergoing cell therapy, documentation of procedure and therapy, safety evaluation, efficacy evaluation, policy of repeated treatments, do not charge patients for unproven therapies, basic principles of cell therapy, and publishing responsibility.
细胞治疗已被证明是中枢神经系统疾病或损伤的一种关键临床治疗选择。为专门从事细胞治疗的专业协会制定细胞治疗临床操作的标准化程序是一项重要任务。国际神经修复学会（IANR）中国分会于 2011 年完成了第一套神经修复临床应用指南。IANR 与中国神经修复学会（CANR）合作提出了当前版本的“神经修复临床细胞治疗指南（IANR/CANR 2017）”。该提案于 2016 年 9 月 1 日获得 IANR 理事会成员和 CANR 委员会成员的批准，并推荐给细胞治疗的临床医生。这些指南包括细胞类型命名、细胞质量控制、最小建议细胞剂量、患者知情同意、进行细胞治疗的适应证、进行细胞治疗的禁忌证、程序和治疗记录、安全性评估、疗效评估、重复治疗政策、不得向未经证实的治疗方法的患者收费、细胞治疗的基本原则和发表责任等项目。
